Kymera Therapeutics Inc

NASDAQ:KYMR

Kymera Therapeutics is a drug development company that tries to treat disease by making harmful proteins disappear inside the body. Instead of blocking a protein the usual way, it designs small-molecule medicines that tag a target protein for the cell’s own disposal system. Its main work is in immunology and cancer, where it is building a pipeline of experimental therapies around this protein-degradation approach. The company does not sell approved medicines to patients. It spends most of its time and money on research, lab testing, and clinical trials, and it may also work with larger drugmakers on selected programs. Kymera’s customers are therefore mostly not end patients but pharmaceutical partners and, eventually, doctors and hospitals if its drug candidates win approval. It makes money mainly through collaboration payments today, and it would also expect future income from milestones, royalties, or product sales if any of its drugs reach the market. What makes Kymera different is its focus on targeted protein degradation, a newer drug category that aims to remove disease-causing proteins rather than just inhibit them. That gives it a place in the drug value chain as an early-stage platform company: it turns chemistry and biology research into candidate medicines, then relies on clinical proof and partnerships to bring those medicines forward.